tetano
Editor, Senior Moderator
J Immunol Res
. 2024 Jan 25:2024:9125398.
doi: 10.1155/2024/9125398. eCollection 2024. Challenges in Emerging Vaccines and Future Promising Candidates against SARS-CoV-2 Variants
Tanmay Ghildiyal[SUP] 1 [/SUP], Nishant Rai[SUP] 2 [/SUP], Janhvi Mishra Rawat[SUP] 2 [/SUP], Maargavi Singh[SUP] 3 [/SUP], Jigisha Anand[SUP] 2 [/SUP], Gaurav Pant[SUP] 4 [/SUP], Gaurav Kumar[SUP] 5 [/SUP], Amrullah Shidiki[SUP] 6 [/SUP]
Affiliations
Since the COVID-19 outbreak, the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) virus has evolved into variants with varied infectivity. Vaccines developed against COVID-19 infection have boosted immunity, but there is still uncertainty on how long the immunity from natural infection or vaccination will last. The present study attempts to outline the present level of information about the contagiousness and spread of SARS-CoV-2 variants of interest and variants of concern (VOCs). The keywords like COVID-19 vaccine types, VOCs, universal vaccines, bivalent, and other relevant terms were searched in NCBI, Science Direct, and WHO databases to review the published literature. The review provides an integrative discussion on the current state of knowledge on the type of vaccines developed against SARS-CoV-2, the safety and efficacy of COVID-19 vaccines concerning the VOCs, and prospects of novel universal, chimeric, and bivalent mRNA vaccines efficacy to fend off existing variants and other emerging coronaviruses. Genomic variation can be quite significant, as seen by the notable differences in impact, transmission rate, morbidity, and death during several human coronavirus outbreaks. Therefore, understanding the amount and characteristics of coronavirus genetic diversity in historical and contemporary strains can help researchers get an edge over upcoming variants.
. 2024 Jan 25:2024:9125398.
doi: 10.1155/2024/9125398. eCollection 2024. Challenges in Emerging Vaccines and Future Promising Candidates against SARS-CoV-2 Variants
Tanmay Ghildiyal[SUP] 1 [/SUP], Nishant Rai[SUP] 2 [/SUP], Janhvi Mishra Rawat[SUP] 2 [/SUP], Maargavi Singh[SUP] 3 [/SUP], Jigisha Anand[SUP] 2 [/SUP], Gaurav Pant[SUP] 4 [/SUP], Gaurav Kumar[SUP] 5 [/SUP], Amrullah Shidiki[SUP] 6 [/SUP]
Affiliations
- PMID: 38304142
- PMCID: PMC10834093
- DOI: 10.1155/2024/9125398
Since the COVID-19 outbreak, the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) virus has evolved into variants with varied infectivity. Vaccines developed against COVID-19 infection have boosted immunity, but there is still uncertainty on how long the immunity from natural infection or vaccination will last. The present study attempts to outline the present level of information about the contagiousness and spread of SARS-CoV-2 variants of interest and variants of concern (VOCs). The keywords like COVID-19 vaccine types, VOCs, universal vaccines, bivalent, and other relevant terms were searched in NCBI, Science Direct, and WHO databases to review the published literature. The review provides an integrative discussion on the current state of knowledge on the type of vaccines developed against SARS-CoV-2, the safety and efficacy of COVID-19 vaccines concerning the VOCs, and prospects of novel universal, chimeric, and bivalent mRNA vaccines efficacy to fend off existing variants and other emerging coronaviruses. Genomic variation can be quite significant, as seen by the notable differences in impact, transmission rate, morbidity, and death during several human coronavirus outbreaks. Therefore, understanding the amount and characteristics of coronavirus genetic diversity in historical and contemporary strains can help researchers get an edge over upcoming variants.